In other contexts, like a specific NASH model, TGR5 activation appeared less critical than FXR activation for therapeutic benefit (85), and in a colon cancer metastasis model, TGR5 downregulation correlated with improved outcomes (101). Here, GPBAR1 is linked to malignant colon neoplasm.